CCR5 antagonism in HIV infection: current concepts and future opportunities.

  title={CCR5 antagonism in HIV infection: current concepts and future opportunities.},
  author={Timothy J. Wilkin and Roy M. Gulick},
  journal={Annual review of medicine},
CCR5 antagonists inhibit HIV-1 entry by blocking the interaction of HIV-1 with the CCR5 cellular receptor. In patients with established HIV-1 infection, some viral strains use an alternative coreceptor for HIV-1 entry, CXCR4; CCR5 antagonists are not effective in patients harboring these viral strains. Coreceptor tropism testing of viral strains in an individual patient is necessary prior to treating with a CCR5 antagonist. There is one CCR5 antagonist, maraviroc, that is FDA-approved for… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…